The Sphingolipid Biosynthetic Pathway Is a Potential Target for Chemotherapy against Chagas Disease. (5th April 2011)

• Record Type: Journal Article
• Authors: Koeller, Carolina Macedo; Heise, Norton
• Other Names: Gonzalez-Rey Elena Academic Editor.
• Is Part Of: Enzyme research. Volume 2011(2011)
• Publication Date: 2011-04-05
• Subjects: Enzymes -- Periodicals; 572.7
• DOI: 10.4061/2011/648159
• Languages: English
• ISSNs: 2090-0406

Abstract

Abstract : The protozoan parasite Trypanosoma cruzi is the causative agent of human Chagas disease, for which there currently is no cure. The life cycle of T. cruzi is complex, including an extracellular phase in the triatomine insect vector and an obligatory intracellular stage inside the vertebrate host. These phases depend on a variety of surface glycosylphosphatidylinositol-(GPI-) anchored glycoconjugates that are synthesized by the parasite. Therefore, the surface expression of GPI-anchored components and the biosynthetic pathways of GPI anchors are attractive targets for new therapies for Chagas disease. We identified new drug targets for chemotherapy by taking the available genome sequence information and searching for differences in the sphingolipid biosynthetic pathways (SBPs) of mammals and T. cruzi . In this paper, we discuss the major steps of the SBP in mammals, yeast and T. cruzi, focusing on the IPC synthase and ceramide remodeling of T. cruzi as potential therapeutic targets for Chagas disease.